Skip to main content

Multiple Sclerosis Trials


ATA188-MS-101, Atara Biotherapeutics

Investigator: J. William Lindsey, MD

Lead CRC: James Jemelka

Purpose: The long term goal is to use white blood cells specific for EBV as a treatment for MS. This is a phase I study in progressive MS, and the main objective is to assess safety and tolerability of the treatment.

Key Inclusion Criteria: Adults 18-65 with PPMS who have not been on exclusionary MS treatments for 30 days.

Enrollment Status: Actively enrolling

Clinical Trials.gov NCT # https://clinicaltrials.gov/show/NCT03283826

Contact Us: To learn more about this trial, please fill out this short online form »


Ocarina: Subcutaneous ocrelizumab, Genentech

Investigator: J. William Lindsey, MD

Lead CRC: James Jemelka

Purpose: To see if Ocrevus can be given SC rather than IV. This study will test whether it can be given by injection under the skin instead of by intravenous infusion, and determine the best dose.

Key Inclusion Criteria: Adults 18-65 with RRMS or PPMS who have been on Ocrelizumab for 1 year with no relapses.

Enrollment Status: Actively enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Elezanumab for neural regeneration, AbbVie

Investigator: J. William Lindsey, MD

Purpose: To see if elezanumab will promote regeneration and repair of damaged brain tissue. It is given by monthly intravenous infusion. There are 3 treatment groups which are placebo, low dose, and high dose. Subjects will remain on their existing treatment and the study drug will be added on.

Key Inclusion Criteria: 18 to 55 years, on a stable treatment for MS for at least 6 months with no expected changes in treatment, and mild to moderate disability.

Enrollment Status: Closed to enrollment

Contact Us: To learn more about this trial, please fill out this short online form »


Evobrutinib, EMD Serono

Investigator: J. William Lindsey, MD

Treatment being tested: Evobrutinib, an agent that inhibits B lymphocytes and macrophages

Purpose: Phase III study to compare the effect of evobrutinib, a new oral agent, to Aubagio, an approved oral medicine.  The phase II results were promising.  Subjects will be randomized to one of the two groups. 

Key inclusion criteria: Relapsing MS.  Age 18 to 55.

Contact Us: To learn more about this trial, please fill out this short online form »


Fenebrutinib, Genentech

Investigator: J. William Lindsey, MD

Treatment being tested: Fenebrutinib, an agent that inhibits B lymphocytes and macrophages

Purpose: Phase III study to compare the effect of fenebrutinib, a new oral agent, to Ocrevus, an approved medicine for PPMS. 

Key inclusion criteria: Primary progressive MS.  Age 18 to 65.

Status: Enrolling August, 2020 

Contact Us: To learn more about this trial, please fill out this short online form »


Ravalizumab, Alexion

Investigator: John Lincoln, MD, PhD

Treatment being tested: Ravalizumab

Purpose: To see if Ravalizumab is effective in neuromyelitis optica (NMO).  This drug is very similar to eculizumab which was recently found to be very effective and approved for treatment of NMO, but should be more convenient since the dosing is less frequent. 

Status: Enrollment ongoing and likely to close soon

Contact Us: To learn more about this trial, please fill out this short online form »


North American Registry for Care and Research in MS (NARCRMS)

Investigator: Rohini Samudralwar, MD

Purpose: To establish a national registry and longitudinal database of clinical and patient-based information related to multiple sclerosis.

Key Inclusion Criteria: Adult patients 18-65 with a clear onset of MS symptoms within the last 15 years.

Enrollment Status: Actively Enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Hormones and Inflammatory Markers in RRMS

Investigator: Rohini Samudralwar, MD

Purpose: To examine the different stages of life and gender, their influence on hormone changes and correlate this with levels of inflammatory markers in the blood that have been associated with RRMS. In addition, this study will be looking at functional status in newly diagnosed patients and those who are having relapses to see if certain key hormones have an influence on overall well-being.

Key Inclusion Criteria: RRMS patients

Enrollment Status: Actively Enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Determining the effectiveness of early intensive versus escalation approaches for RRMS (DELIVER-MS)

Investigator: Rohini Samudralwar, MD

Purpose: To enroll newly diagnosed patients and compare outcomes in a group started on safer, but less effective treatments to the group started on more effective treatments with more potential side effects.

Key Inclusion Criteria: Adults 18-65 with RRMS who have never been on MS treatment

Enrollment Status: Activey Enrolling

Clinical Trials.gov NCT # https://clinicaltrials.gov/show/NCT03535298

Contact Us: To learn more about this trial, please fill out this short online form »


Epstein-Barr Virus & MS

Investigator: J. William Lindsey, M.D.

Purpose: To investigate the connection between EBV and MS and is currently testing whether antibodies to EBV cause damage to brain cells.

Key Inclusion Criteria: Patients willing to donate a blood sample

Enrollment Status: Actively enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Tremor in MS, CDMRP

Investigator: John Lincoln, MD, PhD

Purpose: To figure out what areas and networks in the brain are affected to cause the tremor.

Key Inclusion Criteria: Patients willing to undergo MRI scans

Enrollment Status: Actively enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Features and outcomes of viral infections in sarcoidosis and other ILDs: a prospective study during a pandemic (INSILD)

Investigator: Rohini D. Samudralwar, MD, and Pascal Kingah, MD

Purpose: To track infectious events that subjects with all forms of sarcoidosis report retroactively during prospective follow-up visits.

Key Inclusion Criteria: Adult patient with a diagnosis of sarcoidosis or another ILD and receiving clinical care

Enrollment Status: Actively Enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Enhanced Cerebral Perfusion with Oral Acetazolamide

Investigator: John Lincoln, MD, PhD

Purpose: To see whether acetazolamide will increase brain perfusion. Patients with MS will be treated with oral acetazolamide at different doses and the effect on brain blood flow will be measured with MRI.

Key Inclusion Criteria: 18-55 yrs with relapsing MS who are stable on any of the approved injectable disease modifying therapies

Enrollment Status: Actively Enrolling

Contact Us: To learn more about this trial, please fill out this short online form »

Clinical Trials

Please fill out the fields to receive information about an ongoing UTHealth Neurosciences clinical trial.
  • This field is for validation purposes and should be left unchanged.